Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Tri Budi Hartomo"'
Autor:
Indra Sari Kusuma Harahap, Huyen Thi Van Pham, Noriyuki Nishimura, Richard Hideki Kaszynski, Naoki Yokoyama, Myeong Jin Lee, Tomoto Yamamoto, Hisahide Nishio, Ichiro Morioka, Satoru Morikawa, Yasuhiro Ueno, Dian Kesuma Pramudya, Masafumi Matsuo, Tri Budi Hartomo
Publikováno v:
Genetic Testing and Molecular Biomarkers. 15:677-684
Spinal muscular atrophy (SMA) is a well-defined autosomal recessive neuromuscular disorder caused by mutations in the survival motor neuron 1 (SMN1) gene. The most frequently observed mutation is a deletion of exon 7, which has been documented in95%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3338c0db93448bf36889d7f6f9f4e82b
https://doi.org/10.1089/gtmb.2010.0237
https://doi.org/10.1089/gtmb.2010.0237
Autor:
Takeshi Mori, Nobuyuki Yamamoto, Satoru Morikawa, Tomoto Yamamoto, Myeong Jin Lee, Kazumoto Iijima, Tomoko Yanai, Thi Van Huyen Pham, Noriyuki Nishimura, Yasuhiro Takeshima, Keiichiro Kawasaki, Hisahide Nishio, Ikuko Kubokawa, Tri Budi Hartomo, Hiroki Takeda, Masafumi Matsuo, Akira Hayakawa, Yoshiyuki Kosaka, Daiichiro Hasegawa
Publikováno v:
Environmental Health and Preventive Medicine. 17:246-251
A growing number of epidemiological studies have demonstrated that the consumption of green tea inhibits the growth of a variety of cancers. Epigallocatechin gallate (EGCG), the most abundant catechin in green tea, has been shown to have an anti-canc
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96c611a2c5e44ab8a98e39e0dbffabdd
https://doi.org/10.1007/s12199-011-0239-5
https://doi.org/10.1007/s12199-011-0239-5
Autor:
Tomoko Yanai, Yoshiyuki Kosaka, Keiichiro Kawasaki, Aiko Kozaki, Noriyuki Nishimura, Satoshi Hirase, Kazumoto Iijima, Hisahide Nishio, Daiichiro Hasegawa, Nobuyuki Yamamoto, Takeshi Mori, Tri Budi Hartomo, Akira Hayakawa, Masafumi Matsuo
Neuroblastoma is an aggressive solid tumor that leads to tumor relapse in more than half of high-risk patients. Minimal residual disease (MRD) is primarily responsible for tumor relapses and may be detected in peripheral blood (PB) and bone marrow (B
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::264606e253f8f4b530fde751818c792d
https://europepmc.org/articles/PMC4665349/
https://europepmc.org/articles/PMC4665349/
Autor:
Satoshi Hirase, Hisahide Nishio, Nobuyuki Yamamoto, Atsuro Saitoh, Akira Hayakawa, Masafumi Matsuo, Daiichiro Hasegawa, Takeshi Mori, Aiko Kozaki, Noriyuki Nishimura, Kazumoto Iijima, Yoshiyuki Kosaka, Keiichiro Kawasaki, Tomoko Yanai, Tri Budi Hartomo
Publikováno v:
Oncology letters. 12(2)
Neuroblastoma is an aggressive pediatric tumor accounting for ~15% of cancer-associated mortalities in children. Despite the current intensive therapy, >50% of high-risk patients experience tumor relapse or regrowth caused by the activation of minima
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::da5521ec88653f0ed59f9ebf8f671da1
https://pubmed.ncbi.nlm.nih.gov/27446404
https://pubmed.ncbi.nlm.nih.gov/27446404
Autor:
Yasuhiro Takeshima, Noriyuki Nishimura, Akira Hayakawa, Satoshi Hirase, Hisahide Nishio, Kazumoto Iijima, Yoshiyuki Kosaka, Tri Budi Hartomo, Daiichiro Hasegawa, Thi Van Huyen Pham, Nobuyuki Yamamoto, Masafumi Matsuo
Publikováno v:
International journal of oncology. 46(3)
Despite the introduction of 13-cis-retinoic acid (13-cis-RA) into the current chemotherapy, more than half of high-risk neuroblastoma patients have experienced tumor relapses driven by chemoresistant cancer stem cells (CSCs) that can be isolated by t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d7fc8c819051be82629697da3990ffbf
https://pubmed.ncbi.nlm.nih.gov/25524880
https://pubmed.ncbi.nlm.nih.gov/25524880
Autor:
Hisahide Nishio, Myeong Jin Lee, Akira Hayakawa, Keiichiro Kawasaki, Toshiaki Ishida, Nobuyuki Yamamoto, Takeshi Mori, Noriyuki Nishimura, Thi Van Huyen Pham, Satoru Morikawa, Daiichiro Hasegawa, Ikuko Kubokawa, Tomoko Yanai, Kazumoto Iijima, Yasuhiro Takeshima, Masafumi Matsuo, Tomoto Yamamoto, Tri Budi Hartomo, Yoshiyuki Kosaka
Publikováno v:
Oncology reports. 27(6)
Neuroblastoma is an aggressive pediatric tumor that accounts for 15% of cancer-related deaths in children. More than half of high-risk neuroblastoma patients develop tumor relapse that is lethal in most cases. A small population of tumor-initiating c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b78ccdbd140925ee6c1cf67ecde137d7
https://pubmed.ncbi.nlm.nih.gov/22427180
https://pubmed.ncbi.nlm.nih.gov/22427180
Autor:
Indra Sari Kusuma Harahap, Imam Rusdi, Nur Imma Fatimah Harahap, Huyen Thi Van Pham, Tri Budi Hartomo, Dian Kesumapramudya Nurputra, Satoru Morikawa, Hisahide Nishio, Noriyuki Nishimura, Retno Widiastuti, Richard Hideki Kaszynski, Tomoto Yamamoto
Publikováno v:
Genetic testing and molecular biomarkers. 16(2)
Spinal muscular atrophy (SMA) is a common autosomal recessive neuromuscular disorder. It is caused by mutations in the SMN1, and its clinical severity is modified by copy number variations of the SMN2. According to previous studies, deletion of SMN1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ee2a76bc8c7c9f17c163d3ea96df7376
https://pubmed.ncbi.nlm.nih.gov/21942573
https://pubmed.ncbi.nlm.nih.gov/21942573
Autor:
Masafumi Matsuo, Hisahide Nishio, Nobuyuki Yamamoto, Tomoko Yanai, Takeshi Mori, Yasuhiro Takeshima, Satoru Morikawa, Akira Hayakawa, Ikuko Kubokawa, Myeong Jin Lee, Thi Van Huyen Pham, Daiichiro Hasegawa, Tri Budi Hartomo, Keiichiro Kawasaki, Tomoto Yamamoto, Yoshiyuki Kosaka, Noriyuki Nishimura, Hiroki Takeda
Publikováno v:
Oncology Reports.
Neuroblastoma is the most common extracranial solid tumor in children and accounts for 15% of pediatric cancer deaths. Although retinoic acid (RA) is currently used to treat high-risk neuroblastoma patients in the clinic, RA-responsiveness is variabl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::840625c8025ccd5e3fd34945543d94d5
https://doi.org/10.3892/or.2011.1255
https://doi.org/10.3892/or.2011.1255
Autor:
Noriyuki Nishimura, Masafumi Matsuo, Keiichiro Kawasaki, Akira Hayakawa, Kazumoto Iijima, Satoshi Hrase, Yasuhiro Takeshima, Thi Van Huyen Pham, Tri Budi Hartomo, Daiichiro Hasegawa, Yoshiyuki Kosaka, Nobuyuki Yamamoto, Hisahide Nishio
Publikováno v:
Cancer Research. 74:3857-3857
Neuroblastoma is an aggressive tumor characterized by its heterogeneity ranging from spontaneous regression to malignant progression, and accounts for ∼15% of all cancer-related deaths in children. Despite current aggressive therapies, over 50% of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ee0caa21a4c60605a9eaad9952cc9f85
https://doi.org/10.1158/1538-7445.am2014-3857
https://doi.org/10.1158/1538-7445.am2014-3857